• Imatinib and NET Biology: A Translational Research Agenda

  2026-09-23

  Imatinib (STI571) offers a well-characterized tool for probing Abl, PDGFR, and c-Kit signaling. Paired with emerging evidence on neutrophil extracellular traps in chronic myeloid leukemia, it can help researchers ask a broader question: how does kinase inhibition intersect with immune-cell behavior and vascular biology?

• Gallein Maps Gβγ Control of GPCR Metabolism

  2026-09-23

  Gallein is a G protein βγ subunit inhibitor that can help test whether Gβγ signaling connects lactate-responsive GPR81 to FARP1, RAC1, and GLUT4. This article translates the 2026 Cell Research findings into a rigorous perturbation and assay strategy while defining key interpretation limits.

• Thiamet G in Wnt–O-GlcNAc Bone Biology

  2026-09-22

  Thiamet G is a selective O-GlcNAcase inhibitor for dissecting how O-GlcNAcylation connects Wnt signaling, glycolysis, and osteoblastogenesis. This article translates a recent mechanistic study into practical assay decisions while defining the limits of pharmacological inference.

• Tropifexor (LJN452) FXR Research Workflows

  2026-09-22

  Build mechanism-led FXR experiments with Tropifexor (LJN452), from concentration planning through barrier, metabolic, and liver-model readouts. The workflow separates receptor engagement from phenotype, helping researchers interpret epithelial protection without confusing Tropifexor evidence with findings from unrelated antifibrotic compounds.

• Ivacaftor and Triple CFTR Therapy: In Vitro Evidence

  2026-09-21

  Shaughnessy and colleagues investigated why prolonged ivacaftor exposure can appear to reduce CFTR activity in vitro despite the clinical benefit of ivacaftor-containing therapies. Their Ussing chamber experiments indicate that ivacaftor increases constitutive CFTR-mediated ion transport when combined with tezacaftor and elexacaftor, clarifying its functional importance in triple CFTR modulation.

• Phenytoin and the Early Remodeling of CNS Myelin

  2026-09-21

  A translational framework for using Phenytoin to test how sodium-channel-dependent excitability shapes early myelin swelling, repair, and loss. The article connects longitudinal imaging, electrophysiology, and practical assay design while distinguishing mechanistic hypotheses from established evidence.

• Nadolol: A PK-Aware Research Framework

  2026-09-20

  Nadolol (SQ-11725) is more than a beta-blocking probe: it enables pharmacokinetically informed cardiovascular experiments. This guide connects receptor pharmacology, OATP1A2 transport, and disease-state assay design for more interpretable hypertension, angina, and vascular headache research.

• Dabigatran Acylglucuronide: Potency and Assays

  2026-09-19

  The 2022 Pharmaceutics study directly compared dabigatran with its major active metabolite, dabigatran acylglucuronide, across thrombin generation and routine coagulation assays. Its results show that the metabolite retains anticoagulant activity but is less potent, an observation with practical implications for interpreting metabolite exposure and designing coagulation studies.

• Danazol Workflows for HPG-Axis Research

  2026-09-18

  Danazol offers a defined pharmacological perturbation for studying steroidogenesis, reproductive-axis feedback, and precocious-puberty models. This workflow-focused guide translates a recent rat study into practical stock-preparation, assay-design, comparison, and troubleshooting decisions while distinguishing established findings from optimization recommendations.

• PD 0332991: From G1 Arrest to Translational Insight

  2026-09-18

  PD 0332991 (Palbociclib) HCl is more than a potent CDK4/6 inhibitor: it is a framework for linking Rb biology, cell-cycle control, and interpretable drug-response measurements. This thought-leadership guide shows how translational researchers can use the compound to distinguish growth arrest from cell killing and design more decision-ready oncology studies.

• TROLL-8 mRNA: A Guide to Smarter LNP Studies

  2026-09-17

  TROLL-8 mRNA provides a practical entry point for designing rigorous mRNA delivery experiments. This guide connects product qualification with new evidence on rhamnolipid-stabilized nanoparticles, dendritic-cell targeting, and PEG-free immune activation.

• Magneto-Piezoelectric Scaffolds for Infected Bone Repair

  2026-09-17

  The reference study develops a dual-responsive, 3D-printed scaffold that combines magnetic biofilm disruption with ultrasound-mediated metabolic reprogramming of Icam1+ macrophages. Its central mechanistic finding is that activating JAK2-STAT3 while suppressing MAPK-JNK signaling can restore oxidative phosphorylation and coordinate infection control with bone regeneration.

• VEGFC–Macrophage Axis in NASH Fibrosis

  2026-09-16

  The reference study identifies hepatocyte-derived VEGFC as an upstream regulator of macrophage recruitment and phenotypic remodeling during high-fat diet-induced NASH fibrosis. By combining SAR131675 treatment, hepatocyte-specific Vegfc deletion, patient data, and cell-based experiments, the authors connect VEGFC–VEGFR-3 signaling to CCL2/CCR2-dependent inflammation and impaired Ly6Chigh-to-Ly6Clow macrophage transition.

• Amikacin Sulfate Workflows for Intracellular Infection

  2026-09-16

  Amikacin Sulfate supports a connected research workflow from susceptibility testing and intracellular CFU assays to granuloma-focused delivery studies. This guide shows how to distinguish concentration units, control extracellular carryover, and translate targeted-delivery concepts into more informative antimicrobial experiments.

• G-15: A Causal Tool for GPR30 Signaling

  2026-09-15

  G-15 is a selective G protein-coupled estrogen receptor antagonist for dissecting GPR30 signaling. This article explains how to use it as a causal pharmacology tool in calcium, PI3K/Akt, osteoblast, and estrogen signaling research while avoiding common interpretation errors.

7916 records 1/528 page Next 12345 下5页 Last page